Xinxin Xia

No. 100 Haining Road
Shanghai, 200080, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

Short-course blinatumomab as a bridge-to-transplantation improves the survival of Ph-negative MRD-positive B-ALL.

Short-course blinatumomab as a bridge-to-transplantation improves the survival of Ph-negative MRD-positive B-ALL.

Journal: Cell transplantation

Published: July 07, 2026

Age- and comorbidity-adjusted busulfan, fludarabine, cytarabine, and low-dose TBI-based conditioning regimen is effective for myelodysplastic syndromes with excess blasts undergoing allogeneic peripheral blood stem cell transplantation.

Age- and comorbidity-adjusted busulfan, fludarabine, cytarabine, and low-dose TBI-based conditioning regimen is effective for myelodysplastic syndromes with excess blasts undergoing allogeneic peripheral blood stem cell transplantation.

Journal: Cell transplantation

Published: October 18, 2025

Parous female donor confers superior relapse protection in Haplo-PBSCT: A multicenter study of ATG/PTCy combination-based GVHD prophylaxis in AML/MDS.

Parous female donor confers superior relapse protection in Haplo-PBSCT: A multicenter study of ATG/PTCy combination-based GVHD prophylaxis in AML/MDS.

Journal: Bone marrow transplantation

Published: October 15, 2025

Lymphocyte subset reconstitution and clinical outcomes following haploidentical hematopoietic stem cell transplantation.

Lymphocyte subset reconstitution and clinical outcomes following haploidentical hematopoietic stem cell transplantation.

Journal: British journal of cancer

Published: May 27, 2025

IPSS-M outperforms IPSS-R in prognostic stratification and guides effective interventions for very High-Risk myelodysplastic syndrome patients undergoing allogeneic hematopoietic stem cell transplantation.

IPSS-M outperforms IPSS-R in prognostic stratification and guides effective interventions for very High-Risk myelodysplastic syndrome patients undergoing allogeneic hematopoietic stem cell transplantation.

Journal: Discover oncology

Published: January 31, 2025

Parous female donor is not inferior to the young male donor under the low-dose ATG/PTCy combination-based regimen for GVHD prophylaxis in haploidentical peripheral blood stem cell transplantation.

Parous female donor is not inferior to the young male donor under the low-dose ATG/PTCy combination-based regimen for GVHD prophylaxis in haploidentical peripheral blood stem cell transplantation.

Journal: Leukemia research

Published: January 27, 2025

Epstein-Barr virus reactivation after haplo-peripheral blood stem cell transplantation in patients with hematological malignancies: immune reconstitution and influence on survival.

Epstein-Barr virus reactivation after haplo-peripheral blood stem cell transplantation in patients with hematological malignancies: immune reconstitution and influence on survival.

Journal: Therapeutic advances in hematology

Published: October 21, 2024

Improved survival in older patients with myeloid malignancies undergoing haploidentical peripheral blood stem cell transplantation with low-dose anti-thymocyte globin (ATG)/post-cyclophosphamide (PTCy)-based regimen for graft-versus-host disease prophylaxis.

Improved survival in older patients with myeloid malignancies undergoing haploidentical peripheral blood stem cell transplantation with low-dose anti-thymocyte globin (ATG)/post-cyclophosphamide (PTCy)-based regimen for graft-versus-host disease prophylaxis.

Journal: Annals of hematology

Published: September 15, 2024

Low-dose anti-thymocyte globulin plus low-dose posttransplant cyclophosphamide-based regimen for prevention of graft-versus-host disease in haploidentical peripheral blood stem cell transplantation for pediatric patients with hematologic malignancies.

Low-dose anti-thymocyte globulin plus low-dose posttransplant cyclophosphamide-based regimen for prevention of graft-versus-host disease in haploidentical peripheral blood stem cell transplantation for pediatric patients with hematologic malignancies.

Journal: Annals of hematology

Published: April 23, 2024

Azacitidine combined with interferon-α for pre-emptive treatment of AML/MDS after allogeneic peripheral blood stem cell transplantation: A prospective phase II study.

Azacitidine combined with interferon-α for pre-emptive treatment of AML/MDS after allogeneic peripheral blood stem cell transplantation: A prospective phase II study.

Journal: British journal of haematology

Published: April 05, 2024

Low-dose anti-thymocyte globulin plus low-dose post-transplant cyclophosphamide-based regimen for prevention of graft-versus-host disease after haploidentical peripheral blood stem cell transplants: a large sample, long-term follow-up retrospective study.

Low-dose anti-thymocyte globulin plus low-dose post-transplant cyclophosphamide-based regimen for prevention of graft-versus-host disease after haploidentical peripheral blood stem cell transplants: a large sample, long-term follow-up retrospective study.

Journal: Frontiers in immunology

Published: July 04, 2023

Metagenomic Next-Generation Sequencing for Pathogens in Bronchoalveolar Lavage Fluid Improves the Survival of Patients with Pulmonary Complications After Allogeneic Hematopoietic Stem Cell Transplantation.

Metagenomic Next-Generation Sequencing for Pathogens in Bronchoalveolar Lavage Fluid Improves the Survival of Patients with Pulmonary Complications After Allogeneic Hematopoietic Stem Cell Transplantation.

Journal: Infectious diseases and therapy

Published: June 10, 2023

Showing 1-12 of 22

Last Updated: 09/26/2026